Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-08-16

FDA Approved: GLIADEL — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for GLIADEL (carmustine) by Azurity Pharmaceuticals, Inc. The approval updates the product’s labeling/indication for use…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GLIADEL (Carmustine)

Snippet

SUPPL AP for GLIADEL (CARMUSTINE)